	US 12,282,026 B2
	Method for screening personalized intestinal environment-improving material and composition therefor
Soyoung Park, Suwon-si (KR); and Yosep Ji, Suwon-si (KR)
Assigned to HEM PHARMA INC., Pohang-si (KR)
Filed by HEM PHARMA INC., Pohang-si (KR)
Filed on Dec. 21, 2021, as Appl. No. 17/645,451.
Application 17/645,451 is a continuation of application No. 16/932,626, filed on Jul. 17, 2020, granted, now 11,237,172.
Application 16/932,626 is a continuation in part of application No. PCT/KR2020/001485, filed on Jan. 31, 2020.
Claims priority of application No. 10-2019-0107146 (KR), filed on Aug. 30, 2019.
Prior Publication US 2022/0187305 A1, Jun. 16, 2022 Prior Publication US 2023/0213526 A9, Jul. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 31/00 (2006.01); A61P 1/00 (2006.01); G01N 33/50 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01); A61B 17/00 (2006.01)

CPC G01N 33/6815 (2013.01) [A61P 1/00 (2018.01); G01N 33/5041 (2013.01); G01N 33/5044 (2013.01); A61B 2017/00818 (2013.01)]

17 Claims

1. A method for screening an intestinal environment-improving composition, comprising:

(a) mixing a sample obtained from a subject with medium for screening the intestinal environment-improving composition, and homogenizing the sample, thereby obtaining the sample in medium;

(b) treating the sample in medium from step (a) with the intestinal environment-improving composition and culturing a mixture including the sample in medium and the intestinal environment-improving composition; and

(c) analyzing the cultured mixture from step (b) to determine content or concentration of toxin, intestinal microbiota, microbiota-derived metabolite, or a mixture thereof in the culture thereof,

wherein

the medium for screening the intestinal environment-improving composition does not include protein and carbohydrate; and

the medium for screening the intestinal environment-improving composition comprises L-cysteine.